607 related articles for article (PubMed ID: 26026994)
21. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
[TBL] [Abstract][Full Text] [Related]
23. Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
Iacovelli R; Ciccarese C; Fornarini G; Massari F; Bimbatti D; Mosillo C; Rebuzzi SE; Di Nunno V; Grassi M; Fantinel E; Ardizzoni A; Tortora G
Br J Clin Pharmacol; 2019 Jun; 85(6):1283-1289. PubMed ID: 30740760
[TBL] [Abstract][Full Text] [Related]
24. Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy.
de Barros MVL; Macedo AVS; Sarvari SI; Faleiros MH; Felipe PT; Silva JLP; Edvardsen T
Arq Bras Cardiol; 2019 Jan; 112(1):50-56. PubMed ID: 30569947
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers and prediction of anthracyclic cardiotoxicity in breast cancer.
Silva EN; Ribeiro ML; Caldeira LC; Jorge AJL; Rosa MLG; Mesquita ET; Villacorta H; Martins WA
Rev Assoc Med Bras (1992); 2024; 70(suppl 1):e2024S106. PubMed ID: 38865526
[TBL] [Abstract][Full Text] [Related]
26. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
[TBL] [Abstract][Full Text] [Related]
27. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
Levis BE; Binkley PF; Shapiro CL
Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
[TBL] [Abstract][Full Text] [Related]
28. Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer.
Altundag K
Breast Cancer; 2017 Nov; 24(6):794. PubMed ID: 28275991
[No Abstract] [Full Text] [Related]
29. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
30. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues.
Marwick TH
Can J Cardiol; 2016 Jul; 32(7):842-6. PubMed ID: 27343742
[TBL] [Abstract][Full Text] [Related]
31. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
32. Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?
Chaudry M; Banchs J; Chavez-MacGregor M
Biomark Med; 2016; 10(3):315-28. PubMed ID: 26860187
[TBL] [Abstract][Full Text] [Related]
33. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
[TBL] [Abstract][Full Text] [Related]
34. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Matos E; Jug B; Blagus R; Zakotnik B
Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
[TBL] [Abstract][Full Text] [Related]
35. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.
Narayan V; Keefe S; Haas N; Wang L; Puzanov I; Putt M; Catino A; Fang J; Agarwal N; Hyman D; Smith AM; Finkelman BS; Narayan HK; Ewer S; ElAmm C; Lenihan D; Ky B
Clin Cancer Res; 2017 Jul; 23(14):3601-3609. PubMed ID: 28196874
[No Abstract] [Full Text] [Related]
36. Prospective evaluation of Doppler echocardiography, tissue Doppler imaging and biomarkers measurement for the detection of doxorubicin-induced cardiotoxicity in dogs: A pilot study.
Gallay-Lepoutre J; Bélanger MC; Nadeau ME
Res Vet Sci; 2016 Apr; 105():153-9. PubMed ID: 27033925
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers for monitoring chemotherapy-induced cardiotoxicity.
Cao L; Zhu W; Wagar EA; Meng QH
Crit Rev Clin Lab Sci; 2017 Mar; 54(2):87-101. PubMed ID: 28013560
[TBL] [Abstract][Full Text] [Related]
38. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
Fiúza M
Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
[TBL] [Abstract][Full Text] [Related]
39. Heart failure and chemotherapeutic agents.
Piper S; McDonagh T
Future Cardiol; 2015 Jul; 11(4):453-70. PubMed ID: 26234158
[TBL] [Abstract][Full Text] [Related]
40. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.
De Iuliis F; Salerno G; Taglieri L; De Biase L; Lanza R; Cardelli P; Scarpa S
Tumour Biol; 2016 Mar; 37(3):3379-87. PubMed ID: 26449821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
